DEADLINE ALERT: Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 16, 2022 in TG Therapeutics Lawsuit - TGTX

New York, New York--(Newsfile Corp. - August 8, 2022) - Levi & Korsinsky, LLP notifies investors in TG Therapeutics, Inc. ("TG Therapeutics" or the "Company") (NASDAQ: TGTX) of a class action securities lawsuit.

The lawsuit on behalf of TG Therapeutics investors has been commenced in the the United States District Court for the Southern District of New York. Affected investors purchased or otherwise acquired certain TG Therapeutics, Inc. securities between January 15, 2020 and May 31, 2022. Follow the link below to get more information and be contacted by a member of our team:

https://www.zlk.com/pslra-1/tg-therapeutics-loss-submission-form?prid=30675&wire=5

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.

Cannot view this image? Visit: https://images.newsfilecorp.com/files/7091/133206_465025_logo.jpg

TG Therapeutics, Inc. NEWS - TGTX NEWS

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) clinical trials revealed significant concerns related to the benefit-risk ratio and overall survival data of the Company's therapeutic product candidates, Ublituximab and Umbralisib; (ii) accordingly, it was unlikely that the Company would be able to obtain approval from the U.S. Food and Drug Administration of the Umbralisib marginal zone lymphoma and follicular lymphoma New Drug Application, the Biologics License Application for Ublituximab in combination with Umbralisib, the supplemental New Drug Application for Ublituximab in combination with Umbralisib, or the Ublituximab relapsing forms of multiple sclerosis Biologics License Application in their current forms; (iii) as a result, the Company had significantly overstated Ublituximab and Umbralisib's clinical and/or commercial prospects; and (iv) therefore, the Company's public statements were materially false and misleading at all relevant times.

WHAT THIS MEANS TO SHAREHOLDERS: If you suffered a loss in TG Therapeutics during the relevant timeframe, you have until September 16, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. Discuss your rights with our legal team without cost or obligation.

PROTECT YOUR FINANCIAL INTERESTS: Complete this brief submission form https://www.zlk.com/pslra-1/tg-therapeutics-loss-submission-form?prid=30675&wire=5 or call 212-363-7500 to discuss the case.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/133206

info